Issues in omics data integration for gene set analysis and aberrant pathway identification

Michael F. Ochs

Research output: Contribution to journalArticle

Abstract

The impact of omics technologies, from microarrays to next-generation sequencing, on drug development has been limited by our inability to integrate the data meaningfully for pathway analysis. Here we discuss the relationship between biomolecules and pathway activity, focusing on metabolic and signaling pathways. We discuss how each type of pathway requires a different approach to the generation of pathway statistics from omics data and provide guidance for the creation of appropriate gene sets for pathway analysis.

Original languageEnglish (US)
Pages (from-to)528-534
Number of pages7
JournalDrug Development Research
Volume73
Issue number8
DOIs
StatePublished - Dec 2012

Fingerprint

Metabolic Networks and Pathways
Technology
Pharmaceutical Preparations
Genes

Keywords

  • biostatistics
  • cell signaling
  • gene set analysis
  • metabolic pathway
  • microarray

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Issues in omics data integration for gene set analysis and aberrant pathway identification. / Ochs, Michael F.

In: Drug Development Research, Vol. 73, No. 8, 12.2012, p. 528-534.

Research output: Contribution to journalArticle

@article{e86fdcfc08944ba096636dc176c57fdc,
title = "Issues in omics data integration for gene set analysis and aberrant pathway identification",
abstract = "The impact of omics technologies, from microarrays to next-generation sequencing, on drug development has been limited by our inability to integrate the data meaningfully for pathway analysis. Here we discuss the relationship between biomolecules and pathway activity, focusing on metabolic and signaling pathways. We discuss how each type of pathway requires a different approach to the generation of pathway statistics from omics data and provide guidance for the creation of appropriate gene sets for pathway analysis.",
keywords = "biostatistics, cell signaling, gene set analysis, metabolic pathway, microarray",
author = "Ochs, {Michael F.}",
year = "2012",
month = "12",
doi = "10.1002/ddr.21046",
language = "English (US)",
volume = "73",
pages = "528--534",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Issues in omics data integration for gene set analysis and aberrant pathway identification

AU - Ochs, Michael F.

PY - 2012/12

Y1 - 2012/12

N2 - The impact of omics technologies, from microarrays to next-generation sequencing, on drug development has been limited by our inability to integrate the data meaningfully for pathway analysis. Here we discuss the relationship between biomolecules and pathway activity, focusing on metabolic and signaling pathways. We discuss how each type of pathway requires a different approach to the generation of pathway statistics from omics data and provide guidance for the creation of appropriate gene sets for pathway analysis.

AB - The impact of omics technologies, from microarrays to next-generation sequencing, on drug development has been limited by our inability to integrate the data meaningfully for pathway analysis. Here we discuss the relationship between biomolecules and pathway activity, focusing on metabolic and signaling pathways. We discuss how each type of pathway requires a different approach to the generation of pathway statistics from omics data and provide guidance for the creation of appropriate gene sets for pathway analysis.

KW - biostatistics

KW - cell signaling

KW - gene set analysis

KW - metabolic pathway

KW - microarray

UR - http://www.scopus.com/inward/record.url?scp=84870944613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870944613&partnerID=8YFLogxK

U2 - 10.1002/ddr.21046

DO - 10.1002/ddr.21046

M3 - Article

VL - 73

SP - 528

EP - 534

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 8

ER -